Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-303: First-line tarlatamab + platinum/etoposide + PD-L1 inhibitor in extensive-stage small cell lung cancer
jRCT2031220277Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of tarlatamab in small cell lung cancer (SCLC) (9 arms), sponsored by Amgen. Primary endpoints: Number of participants with a dose limiting toxicity (DLT), Number of participants with treatment-emergent adverse events (TEAEs and 4 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031220277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220277.